Numerous studies have confirmed that the expression of GPX2 is significantly upregulated in gastrointestinal tumors, liver tumors, glioblastoma, lung adenocarcinoma, breast cancer, and other cells [10–15]. This evidence concerns the gene GPX2 and lung adenocarcinoma.